Spark Therapeutics (ONCE) : Traders are bullish on Spark Therapeutics (ONCE) as it has outperformed the S&P 500 by a wide margin of 13.83% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 11.17%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 11.76% in the last 1 week, and is up 11.53% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 10.82% and the 50-Day Moving Average is 11.91%.The 200 Day SMA reached 46.3% Spark Therapeutics, Inc. is up 39.53% in the last 3-month period. Year-to-Date the stock performance stands at 40.92%.
Spark Therapeutics (ONCE) : The consensus price target for Spark Therapeutics (ONCE) is $62.44 for the short term with a standard deviation of $20.38. The most optimist securities analyst among the 9 who monitor the stock believes that the stock can reach $94, however, the pessimist price target for the company is $28.
Company shares have received an average consensus rating of Hold for the current week Spark Therapeutics (NASDAQ:ONCE): The stock opened at $63.03 and touched an intraday high of $64 on Friday. During the day, the stock corrected to an intraday low of $61.1, however, the bulls stepped in and pushed the price higher to close in the green at $63.85 with a gain of 2.59% for the day. The total traded volume for the day was 931,653. The stock had closed at $63.85 in the previous trading session.
Spark Therapeutics, Inc. (Spark) is engaged in developing products in the field of gene therapy. Sparks product candidate, SPK-RPE65, which is in Phase III clinical trial stage, targets a group of rare blinding conditions known as inherited retinal dystrophies (IRDs), caused by non-sex linked or autosomal recessive mutations in the RPE65 gene. Spark is also developing various follow-on product candidates targeting other IRDs, including SPK-CHM for the treatment of choroideremia (CHM). SPK-CHM is in Phase I/II dose-escalating clinical trial stage. The Companys product development portfolio includes product candidates targeting expression of genes in the liver, with a focus on hematologic disorders. The Company is also engaged in the development and commercialization of product candidates in its SPK-FIX program for the treatment of hemophilia B. Spark also has preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases.